Stock APLS APELLIS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Apellis Pharmaceuticals, Inc.

Equities

APLS

US03753U1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
47.84 USD -4.05% Intraday chart for Apellis Pharmaceuticals, Inc. +0.42% -20.08%
01:31pm Mizuho Securities Cuts Price Target on Apellis Pharmaceuticals to $52 From $60, Maintains Neutral Rating MT
Apr. 26 Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
GL
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
GL
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
GL
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
AQ
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
GL
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
GL
Apellis Pharmaceuticals Announces Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
GL
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
GL
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Apellis Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. APLS Stock
  4. News Apellis Pharmaceuticals, Inc.
  5. Press Releases